Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). Materials and methods. We analyzed cost minimization, impact on the budget and...
Saved in:
| Main Authors: | S. V. Nedogoda, A. S. Salasyuk, E. V. Bobykin, I. N. Barykina, V. O. Smirnova, E. A. Popova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2020-03-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01) -
Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01) -
Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01) -
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01) -
Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration
by: Onur Polat, et al.
Published: (2017-08-01)